Search CommunityWalk:
Create_a_map_small
Mymaps_small



Blank

Omnia Biologics, Inc.

Address:
12111 Parklawn Drive
--
Rockville, MD, USA
1-866-316-6642

Category: BioManufacturing; Research Services & Supplies; Suppliers (CRO)

Used in the following map:

Maryland Biotech Industry Map

Omnia Biologics offers translational medicine services in the areas of process development, assay development, GMP manufacture, and fill-finish for preclinical and clinical programs for therapeutics. These include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company has established relationships with both biopharmaceutical companies and academic investigators. Its mission is to address the process development (PD) and manufacturing needs of individual investigators and organizations requiring flexible, pre-clinical and Phase I/II GMP manufacturing services for novel biologics. Its focus is on Viral based products and cell therapeutics.

Omnia's technical focus include: Adenovirus, Lentivirus, Retrovirus, AAV, VLP and Other viral platforms. It provides a full array of services for early stage therapeutics. Its services include: Manufacturing, Process Development, Cell and Virus Banking and Aseptic Filling.

Omnia produces preclinical and GMP Phase I/II clinical materials used in vaccine and gene therapy applications. Its process development (PD) goals include: Maximizing the production capacity of a therapeutic platform, Reducing manufacturing costs, etc. Its aseptic filling services include: GMP aseptic filling of viral and infectious materials, Documented to meet FDA requirements for Phase I/II clinical manufacture and Pricing is based on small runs for a small, not large and facility. Its Cell and Virus banks include: Mammalian cell banks and viral seed stocks.

Omnia Biologics has agreement with Biotech Experts, Inc., Aparna Biosciences Corp., Potentia Pharmaceuticals, Aeras Global TB Vaccine Foundation, AFG Biosolutions, Prolong Pharmaceuticals, Lentigen Corporation, Intradigm Corporation, University of Maryland and AT-GC BioPharm.